Abstract:Therapeutic Advances in Drug Safety, Volume 15, Issue , January-December 2024. Objectives:This pharmacovigilance analysis was conducted to assess the safety signals of FMS-related tyrosine kinase 3 (FLT3) inhibitors in a real-world setting using the United States Food and Drug Administration Adverse Event Reporting System (FAERS).Design:We analyzed adverse event (AE) reports related to FLT3 inhibitors submitted to the FAERS database from the first quarter of 2015 to the fourth quarter of 2022. Disproportionality analysis was used to identify AEs of FLT3 inhibitors in the FAERS database.Results:A total of 55,393 AE reports were identified, of which 5938, 44,013, and 5442 were attributed to midostaurin, sorafenib, and gilteritinib, respectively, as primary suspects. Compared to the full database, significant safety signals at the system organ class level were observed for midostaurin (blood and lymphatic system disorders and hepatobiliary disorders), sorafenib (skin and subcutaneous tissue disorders and hepatobiliary disorders), and gilteritinib (investigations, blood and lymphatic system disorders, infections and infestations, and hepatobiliary disorders). All the drugs studied were associated with hepatobiliary disorders. The most prominent AEs associated with midostaurin, sorafenib, and gilteritinib were cytopenia, palmar-plantar erythrodysesthesia syndrome, and increased blast cell count, respectively. Compared with chemotherapy, midostaurin and gilteritinib showed a higher risk of electrocardiogram QT prolongation, gastrointestinal hemorrhage, cerebral hemorrhage, and increased white blood cell count. Gilteritinib had the highest overall death percentage (30.28%), whereas sorafenib had the lowest (23.06%).Conclusion:Mining AE signals using the FAERS database provides a method for analyzing the safety of FLT3 inhibitors in post-marketing. We found several significant AE signals that corresponded to previous studies; however, some AE signals were not mentioned in the drug instructions. Our study could provide a direction for follow-up real-world studies to verify the results further.Plain language summaryA study on the adverse effects of FLT3 inhibitorsIntroduction:The United States Food and Drug Administration Adverse Event Reporting System (FAERS) is an essential tool for the United States Food and Drug Administration (FDA) to detect adverse events (AE). This study explored the safety signals of FMS-related tyrosine kinase 3 (FLT3) inhibitors (midostaurin, sorafenib, and gilteritinib) using the FAERS database.Research design and methods:We used reporting odds ratios, proportional reporting ratios, and Bayesian confidence propagation neural network to analyze the safety signals of FLT3 inhibitors by comparing them with the full database and chemotherapy agents from 2015 to 2022.Results:A total of 5,938, 44,013, and 5,442 reports were attributed to midostaurin, sorafenib, and gilteritinib, respectively. Based on the analysis results, we observed the following:• Regarding the analysis of system organ class level compared with the full database, "hepatobiliary disorders" appeared as an important signal in all three drugs. In addition, "blood and lymphatic system disorders" of midostaurin, "skin and subcutaneous tissue disorders" of sorafenib, and "investigations," "blood and lymphatic system disorders," and "infections and infestations" of gilteritinib were significant.• Cytopenia was the most prominent AE associated with midostaurin in comparisons of midostaurin versus the full database, and electrocardiogram QT prolonged was the strongest signal in comparisons of midostaurin versus chemotherapy.• In both comparisons of FLT3 inhibitors versus the full database and chemotherapy, the strongest safety signals of sorafenib and gilteritinib were palmar-plantar erythrodysesthesia syndrome and increased blast cell count, respectively.• Gilteritinib exhibited the highest overall mortality rate, whereas sorafenib had the lowest.Conclusion:We identified several significant AE signals that corresponded to previous studies. However, some AE signals were not mentioned in the drug instructions. The AE signals should be evaluated further based on real-world data in the future.

Fluid retention-associated adverse events in patients treated with BCR::ABL1 inhibitors based on FDA Adverse Event Reporting System (FAERS): a retrospective pharmacovigilance study

Cardiovascular and pulmonary adverse events in patients treated with BCR-ABL inhibitors: Data from the FDA Adverse Event Reporting System

Pharmacovigilance evaluation of the relationship between impaired glucose metabolism and BCR-ABL inhibitor use by using an adverse drug event reporting database

A disproportionality analysis for assessing the safety of FLT3 inhibitors using the FDA Adverse Event Reporting System (FAERS)

A Real-World Disproportionality Analysis of FDA Adverse Event Reporting System (FAERS) Events for Baricitinib.

Data mining and safety analysis of BTK inhibitors: A pharmacovigilance investigation based on the FAERS database

Real-World Disproportionality Analysis of the Food and Drug Administration Adverse Event Reporting System Database for Asciminib

A disproportionality analysis of CDK4/6 inhibitors in the FDA Adverse Event Reporting System (FAERS)

Pharmacovigilance study of BCR-ABL1 tyrosine kinase inhibitors: a safety analysis of the FDA adverse event reporting system

Safety assessment of KRAS (G12C) inhibitors based on the FDA Adverse Event Reporting System (FAERS) database: A real-world pharmacovigilance study

Pharmacovigilance Study of Infigratinib: A Safety Analysis of the FDA Adverse Event Reporting System

A disproportionality analysis of sunitinib in the FDA adverse event reporting system (FAERS)

A real-world study of antifibrotic drugs-related adverse events based on the United States food and drug administration adverse event reporting system and VigiAccess databases

A post-marketing pharmacovigilance study of avapritinib: Adverse event data mining and analysis based on the United States Food and Drug Administration Adverse Event Reporting System database

Healthcare and economic burden of adverse events among patients with chronic myelogenous leukemia treated with BCR-ABL1 tyrosine kinase inhibitors

A real-world pharmacovigilance study of polatuzumab vedotin based on the FDA adverse event reporting system (FAERS)

Novel Insights into Post-Marketing Adverse Events Associated with Lenvatinib: A Comprehensive Analysis Utilizing the FAERS Database

A real-world disproportionality analysis of sacubitril/valsartan: data mining of the FDA adverse event reporting system

Case report: Pemigatinib-induced retinopathy: a serial examination of subretinal fluid secondary to an FGFR inhibitor

Disseminated intravascular coagulation is an underestimated but fatal adverse event associated with blinatumomab therapy: A pharmacovigilance analysis of FAERS

Disproportionality Analysis of Abemaciclib in the FDA Adverse Event Reporting System: A Real-World Post-Marketing Pharmacovigilance Assessment